首页> 外国专利> COMBINATION OF SOMATOSTATIN ANALOGUES WITH DOPAMINE RECEPTOR OR GROWTH HORMONE RECEPTOR ANTAGONIST

COMBINATION OF SOMATOSTATIN ANALOGUES WITH DOPAMINE RECEPTOR OR GROWTH HORMONE RECEPTOR ANTAGONIST

机译:生长抑素类似物与多巴胺受体或生长激素受体拮抗剂的组合

摘要

1. A combination containing (a) sandostatin® LAR® and (b) a second active compound selected from the group consisting of a dopamine agonist and growth hormone receptor antagonist, in the form of a combined preparation for simultaneous, separate or sequential administration in the treatment of acromegaly, wherein said Sandostatin® LAR® is administered at a dose of 40 mg / 28 days. ! 2. The combination according to claim 1, characterized in that said combination preparation is used to treat patients with acromegaly who do not observe normalization of biochemical markers after treatment for at least 6 months using at least one somatostatin analogue during the standard course of treatment. ! 3. The combination according to claim 2, characterized in that during the specified standard course of treatment, 30 mg of Sandostatin® LAR® is administered every 28 days. ! 4. The combination according to claim 3, characterized in that said combination preparation is administered for at least 4 months. ! 5. The combination according to claim 4, characterized in that a dose of 40 mg of said sandostatin® LAR® is administered by two injections of 20 mg each. ! 6. The combination according to claim 5, characterized in that said sandostatin® LAR® is administered by intramuscular injection. ! 7. The combination according to claim 1, characterized in that said second active compound is a dopamine agonist. ! 8. The combination according to claim 7, characterized in that said dopamine agonist is cabergoline. ! 9. The combination of claim 8, wherein the dose of said cabergoline is 0.5-3.5 mg per week. ! 10. The combination according to claim 9, characterized in that the specified dose of cabergoline is! during the first week of treatment 0.5 mg,! during the second week of treatment
机译:1.一种组合物,其包含用于同时,分开或依次给药的组合制剂的形式,所述组合包含(a)sandostatin®LAR®和(b)第二活性化合物,所述第二活性化合物选自多巴胺激动剂和生长激素受体拮抗剂。治疗肢端肥大症,其中所述Sandostatin®LAR®以40 mg / 28天的剂量给药。 ! 2.根据权利要求1所述的组合,其特征在于,所述组合制剂用于在标准治疗过程中使用至少一种生长抑素类似物治疗至少6个月后未观察到生化标志物正常化的肢端肥大症患者。 ! 3.根据权利要求2所述的组合,其特征在于,在规定的标准治疗过程中,每28天施用30mg的Sandostatin®LAR。 ! 4.根据权利要求3所述的组合,其特征在于,所述组合制剂被施用至少4个月。 ! 5.根据权利要求4所述的组合,其特征在于,通过两次每次20mg的注射来施用40mg的所述剂量。 ! 6.根据权利要求5所述的组合,其特征在于,所述sandostatin®LAR®通过肌内注射给药。 ! 7.根据权利要求1的组合,其特征在于,所述第二活性化合物是多巴胺激动剂。 ! 8.根据权利要求7的组合,其特征在于所述多巴胺激动剂是卡麦角林。 ! 9.权利要求8的组合,其中所述卡麦角林的剂量为每周0.5-3.5mg。 ! 10.根据权利要求9的组合,其特征在于卡麦角林的指定剂量为!在治疗的第一周内0.5毫克!在治疗的第二周

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号